Applied Graphene Materials plc (APGMF)
USD 0.0
(-99.6%)
USD 0.0
(-99.6%)
| Breakdown | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.56 Million | -2.1 Million | -4.11 Million | -3.32 Million | -2.67 Million | -3.95 Million |
| Net Income | -3.17 Million | -3.18 Million | -3.92 Million | -3.49 Million | -4.31 Million | -4.57 Million |
| Depreciation & Amortization | 818 Thousand | 892 Thousand | 686 Thousand | 622 Thousand | 251 Thousand | 169 Thousand |
| Deferred income taxes | -345 Thousand | 267 Thousand | -1.17 Million | -859 Thousand | 1.31 Million | 288 Thousand |
| Stock-based compensation | 32 Thousand | -14 Thousand | 294 Thousand | 177 Thousand | 192 Thousand | 235 Thousand |
| Change in working capital | 99 Thousand | -199 Thousand | 72 Thousand | -12 Thousand | -95 Thousand | -14 Thousand |
| Other non-cash items | 6000.00 | 135 Thousand | -67 Thousand | 250 Thousand | -33 Thousand | 233 Thousand |
| Investing Cash Flow | -218 Thousand | -342 Thousand | -193 Thousand | -319 Thousand | -725 Thousand | -1.08 Million |
| Investments in PPE | -218 Thousand | -342 Thousand | -193 Thousand | -319 Thousand | -725 Thousand | -1.08 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -151 Thousand | - | - | - | - | -97 Thousand |
| Financing Cash Flow | 5.4 Million | - | - | 9.37 Million | 407 Thousand | 8.03 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 5.55 Million | - | - | 9.37 Million | 407 Thousand | 8.03 Million |
| Other Financing Activities | -147 Thousand | - | - | - | - | - |
| Accounts receivables | -29 Thousand | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -19 Thousand | -22 Thousand | 4000.00 | -10 Thousand | -6000.00 | -14 Thousand |
| Other working capital | 118 Thousand | -177 Thousand | 68 Thousand | -2000.00 | -89 Thousand | - |
| Cash at beginning of period | 3.68 Million | 6.13 Million | 10.44 Million | 4.7 Million | 7.7 Million | 4.7 Million |
| Cash at end of period | 6.3 Million | 3.68 Million | 6.13 Million | 10.44 Million | 4.7 Million | 7.7 Million |
| Capital Expenditure | -218 Thousand | -342 Thousand | -193 Thousand | -319 Thousand | -725 Thousand | -1.08 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 2.62 Million | -2.45 Million | -4.3 Million | 5.73 Million | -2.99 Million | 2.99 Million |
| Free Cash Flow | -2.78 Million | -2.45 Million | -4.3 Million | -3.64 Million | -3.4 Million | -5.03 Million |
| Breakdown | 2023 Q4 | 2023 Q2 | 2022 Q2 | 2021 FY | 2021 Q4 | 2021 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | -2.3 Million | -3.17 Million | -2.16 Million | -2.13 Million |
| Depreciation & Amortization | - | - | 248.6 Thousand | 818 Thousand | 271.32 Thousand | 282.77 Thousand |
| Deferred income taxes | - | - | - | -345 Thousand | - | - |
| Stock-based compensation | - | - | - | 32 Thousand | - | - |
| Change in working capital | - | - | -313.81 Thousand | 99 Thousand | -148.99 Thousand | 286.73 Thousand |
| Other non-cash items | - | - | 270.34 Thousand | 6000.00 | 713.25 Thousand | 438.69 Thousand |
| Investing Cash Flow | - | - | -154.87 Thousand | -218 Thousand | -163.25 Thousand | -140.06 Thousand |
| Investments in PPE | - | - | -154.87 Thousand | -218 Thousand | -163.25 Thousand | -140.06 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | -89.66 Thousand | 5.4 Million | 7.52 Million | -9249.61 |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 5.55 Million | 7.63 Million | 93.81 Thousand |
| Other Financing Activities | - | - | - | -147 Thousand | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | -19 Thousand | - | - |
| Other working capital | - | - | - | 118 Thousand | - | - |
| Cash at beginning of period | - | - | 8.77 Million | 3.68 Million | 3.14 Million | 4.83 Million |
| Cash at end of period | - | - | 5.65 Million | 6.3 Million | 8.77 Million | 3.14 Million |
| Capital Expenditure | - | - | -154.87 Thousand | -218 Thousand | -163.25 Thousand | -140.06 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | -3.11 Million | 2.62 Million | 5.62 Million | -1.69 Million |
| Free Cash Flow | - | - | -2.75 Million | -2.78 Million | -2.03 Million | -1.83 Million |
AJANTPHARM
SMAYF
SHO
JNVR
TTNDF
ROI